Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661672 · ClinicalTrials.gov registry record · NA
INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage
A NA study of Intracranial Hemorrhage, sponsored by J. Moc.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 7
- Study locations
NCT02661672: Completed NA study of Intracranial Hemorrhage, sponsored by J. Moc.
NCT02661672 is a NA study of Intracranial Hemorrhage that has completed, run by J. Moc. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661672, a NA study of Intracranial Hemorrhage, has completed, sponsored by J. Moc.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 7
- Study locations
Study Summary
Objective: The primary objective of this multicenter prospective registry is to provide additional safety, technical outcomes and clinical outcomes data for minimally invasive endoscopic surgery (MIES) with Apollo or Artemis for the evacuation of supratentorial brain hemorrhage in adult patients who do not qualify for the concurrent INVEST Feasibility randomized controlled trial at active INVEST centers.
Primary Outcome
Clinical Efficacy Endpoint: global disability assessed via the modified Rankin score (mRS). 180-day global disability assessed via the modified Rankin score (mRS), categorized as either mRS ≤ 3 or mRS \> 3
Conditions Studied
Interventions
- DEVICE Apollo Device
- DEVICE Artemis Device
Study Locations (7)
New York
- University of Buffalo - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
District of Columbia
- George Washington University - Washington D.C.
Kentucky
- University of Louisville - Louisville
Pennsylvania
- Geisinger Medical Center - Danville
South Carolina
- Prisma Health - Greenville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2022-11-16 |
| Phase | NA |
What the finished NCT02661672 record still lists
NCT02661672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Intracranial Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Apollo Device is the first listed.
NCT02661672 lists 7 locations in 6 states (New York, District of Columbia, Kentucky).
Frequently Asked Questions
What is clinical trial NCT02661672 about?
NCT02661672 is a clinical study titled "INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage". Objective: The primary objective of this multicenter prospective registry is to provide additional safety, technical outcomes and clinical outcomes data for minimally invasive endoscopic surgery (MIES) with Apollo or Artemis for the evacuation of supratentorial brain hemorrhage in adult patients who...
What is the current status of trial NCT02661672?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2016-10-14. Estimated completion is 2022-11-16.
What conditions does trial NCT02661672 study?
This clinical trial studies the following conditions: Intracranial Hemorrhage.
What interventions are being tested in trial NCT02661672?
The interventions under investigation include: Apollo Device (DEVICE), Artemis Device (DEVICE).
Who is sponsoring clinical trial NCT02661672?
This trial is sponsored by J. Moc, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02661672 being conducted?
This trial has 7 study locations across District of Columbia, Kentucky, New York, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracranial Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02661672's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI